Population Pharmacokinetics and Exposure — Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaXiaoli Wang, Matthew Hruska, Akintunde Bello et al.|The Journal of Clinical Pharmacology|2018Cited by 17